IRIS
SILVESTRIS, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.983
AS - Asia 5.748
EU - Europa 4.362
SA - Sud America 1.593
AF - Africa 274
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 29.973
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.700
SG - Singapore 2.577
IT - Italia 1.376
BR - Brasile 1.265
CN - Cina 984
HK - Hong Kong 758
SE - Svezia 738
RU - Federazione Russa 601
FR - Francia 430
VN - Vietnam 372
GB - Regno Unito 289
DE - Germania 265
IN - India 227
BD - Bangladesh 164
CA - Canada 134
FI - Finlandia 127
BE - Belgio 111
AR - Argentina 103
TR - Turchia 99
IQ - Iraq 78
ZA - Sudafrica 78
ID - Indonesia 76
MX - Messico 74
UA - Ucraina 68
JP - Giappone 59
CI - Costa d'Avorio 58
CO - Colombia 56
EC - Ecuador 49
PK - Pakistan 49
PL - Polonia 49
VE - Venezuela 49
ES - Italia 47
CZ - Repubblica Ceca 39
NL - Olanda 31
AT - Austria 30
SA - Arabia Saudita 30
UZ - Uzbekistan 29
MA - Marocco 25
AE - Emirati Arabi Uniti 23
MY - Malesia 22
IE - Irlanda 20
CL - Cile 19
ET - Etiopia 19
PH - Filippine 19
JO - Giordania 18
KE - Kenya 18
LT - Lituania 18
IL - Israele 17
NP - Nepal 17
BG - Bulgaria 15
BO - Bolivia 15
DZ - Algeria 15
IR - Iran 15
TN - Tunisia 14
CH - Svizzera 13
EG - Egitto 13
PY - Paraguay 13
JM - Giamaica 12
CR - Costa Rica 11
PT - Portogallo 11
RS - Serbia 11
KR - Corea 10
UY - Uruguay 10
HR - Croazia 9
KZ - Kazakistan 9
PE - Perù 9
QA - Qatar 9
SY - Repubblica araba siriana 9
AZ - Azerbaigian 8
BH - Bahrain 8
HN - Honduras 8
KW - Kuwait 8
RO - Romania 8
DO - Repubblica Dominicana 7
KG - Kirghizistan 7
PA - Panama 7
TT - Trinidad e Tobago 7
AL - Albania 6
DK - Danimarca 6
HU - Ungheria 6
LB - Libano 6
LY - Libia 6
TH - Thailandia 6
BY - Bielorussia 5
LV - Lettonia 5
NO - Norvegia 5
PS - Palestinian Territory 5
SR - Suriname 5
AO - Angola 4
AU - Australia 4
BB - Barbados 4
GE - Georgia 4
NI - Nicaragua 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
AM - Armenia 3
BW - Botswana 3
GR - Grecia 3
GT - Guatemala 3
LA - Repubblica Popolare Democratica del Laos 3
Totale 29.899
Salva come PNG Salva come JPEG
Città #
Ashburn 2.140
Fairfield 2.052
Chandler 1.759
Singapore 1.442
Woodbridge 1.028
Seattle 919
San Jose 910
Cambridge 906
Houston 855
Hong Kong 751
Wilmington 655
Milan 593
Nyköping 564
Ann Arbor 395
Beijing 390
Dallas 312
Los Angeles 273
New York 251
Lawrence 244
Lauterbourg 234
Roxbury 229
Rome 203
Council Bluffs 172
Des Moines 149
Santa Clara 129
Columbus 121
The Dalles 120
Ho Chi Minh City 113
Brussels 109
Paris 109
Brooklyn 107
São Paulo 103
San Diego 99
Inglewood 91
Dearborn 89
Munich 87
Hanoi 85
London 83
Jacksonville 80
Helsinki 78
Moscow 74
Atlanta 67
Chicago 65
Boardman 61
Abidjan 58
Denver 57
Pune 57
Tokyo 56
Figino 55
Frankfurt am Main 54
Phoenix 53
Bari 52
San Francisco 50
Montreal 47
Orem 46
Jakarta 45
Buffalo 44
Turin 41
Warsaw 41
Nanjing 40
Rio de Janeiro 39
Washington 36
Chennai 33
Johannesburg 32
Baghdad 29
Turku 28
Mexico City 27
San Mateo 27
Brasília 26
Brno 26
Edinburgh 26
Tashkent 26
Ankara 25
Belo Horizonte 25
Falkenstein 25
Toronto 25
Boston 24
Da Nang 23
Falls Church 23
Guangzhou 23
Porto Alegre 23
Princeton 23
Stockholm 23
Dong Ket 22
Poplar 21
Vienna 21
Amsterdam 20
Dublin 20
Jinan 20
Ruvo Di Puglia 20
Shanghai 20
Bologna 19
Istanbul 19
Mumbai 19
Charlotte 18
Addis Ababa 17
Campinas 17
Hefei 17
Monmouth Junction 17
Norwalk 17
Totale 21.033
Salva come PNG Salva come JPEG
Nome #
Molecularly targeted endocrine therapies for breast cancer 1.017
Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity 256
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 255
Angiogenesis in adenosquamous cancer of pancreas 226
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 213
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells 207
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 192
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study 188
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 183
Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma 183
Targeting angiogenesis in biliary tract cancers: An open option 173
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 173
NHERF1 and tumor microenvironment: A new scene in invasive breast carcinoma 172
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 172
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 170
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence 166
Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence 165
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 163
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 163
Adjuvant colon cancer chemotherapy: Where we are and where we'll go 163
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 162
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 162
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 161
Bone metastases in biliary cancers: A multicenter retrospective survey 161
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 160
The European accreditation of Istituto Tumori Giovanni Paolo II of Bari 158
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 158
Carcinogenesis of pancreatic adenocarcinoma: Precursor lesions 157
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 157
Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis with a focus on epithelial to mesenchymal transition 156
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 155
[Apoptosis or programmed cell death: regulatory and pathophysiological mechanisms]. FT Apoptosi, o morte cellulare programmata: meccanismi regolatori e fisiopatologia. 154
Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study 154
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 153
mTOR as a target of everolimus in refractory/relapsed Hodgkin Lymphoma 153
Should tumor infiltrating lymphocytes, androgen receptor, and FOXA1 expression predict the clinical outcome in triple negative breast cancer patients? 151
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 149
The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy 148
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 147
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 147
Challenges and opportunities of MicroRNAs in lymphomas 146
Adjuvant therapy in colon cancer 146
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside 146
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity 146
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 145
Co-expression of CD133+/CD44+ in human colon cancer and liver metastasis 144
Target therapies in pancreatic carcinoma 143
Immunotherapeutic approaches for hepatocellular carcinoma 142
Synthetic lethality to overcome cancer drug resistance 142
Antineoplastic drug-induced bradyarrhythmias 142
IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity 141
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 141
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 141
Molecular classifications of gastric cancers: Novel insights and possible future applications 141
Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype 141
How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis 140
Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: The gastric life nomogram 140
Combined modality treatments in pancreatic cancer 139
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: From biological principles to clinical guidelines 139
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 139
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 139
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 138
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 138
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 137
Oncosuppressor methylation: A possible key role in colon metastatic progression 137
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 137
Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine 137
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 136
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 136
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 136
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer 136
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: An open issue 136
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 136
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 135
New molecular targets in bone metastases 135
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 134
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 134
HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives 134
Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey 134
p53 as the main traffic controller of the cell signaling network 133
A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery 132
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 132
Current status of targeted therapies in advanced gastric cancer 132
Actors on the scene: Immune cells in the myeloma niche 132
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 131
CES2, ABCG2, TS and topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen 130
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice 130
Fas/Fas-ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells 129
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 129
Hydroxy-propil-β-cyclodextrin inclusion complexes of two biphenylnicotinamide derivatives: Formulation and anti-proliferative activity evaluation in pancreatic cancer cell models 129
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 128
Laparoscopic vs. open mesorectal excision for rectal cancer: Are these approaches still comparable? A systematic review and metaanalysis 128
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma 127
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 127
Advances in EGFR-directed therapy in head and neck cancer 127
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials 126
High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression 125
Immunotherapy for colorectal cancer: where are we heading? 124
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 124
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 123
Totale 15.830
Salva come PNG Salva come JPEG
Categoria #
all - tutte 138.218
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 138.218
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.191 154 209 40 77 159 149 110 133 142 111 224 683
2022/20233.687 399 514 291 360 316 413 111 474 541 25 203 40
2023/20241.168 84 216 80 101 123 322 19 66 9 28 10 110
2024/20254.546 95 82 359 207 153 513 381 418 162 222 734 1.220
2025/202610.765 1.489 407 596 826 1.278 530 1.132 306 1.050 776 907 1.468
2026/2027350 350 0 0 0 0 0 0 0 0 0 0 0
Totale 30.566